ReciBioPharm
Keele, UK · Sodertalje, SE
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
88.0
Signal Score
○ FDA Inspections
○ Clinical Trials
✓ SEC Filings (13)
○ Press
○ EMA GMP
✓ MHRA GMP (3)
Quick Facts: ReciBioPharm
- Signal Score
- 88.0/100 (as of 2026-09-07)
- Quality Compliance
- 100.0/100
- Headquarters
- Keele, UK · Sodertalje, SE
- Modalities
- AAV, Lentiviral, Plasmid, mRNA
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About ReciBioPharm
Formerly Cobra Biologics. Acquired by CRL.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
100.0
FDA InspectionsNo US records on file
MHRA GMP Certificates3 on record
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid, mRNA
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
74.0
13 SEC filings with industry mentions on record
SEC Filings13 with industry mentions
Capacity
81.0
Profile-based capacity assessment
ReciBioPharm MHRA GMP Compliance 3 certificates
2020-12
2020-12
2019-01
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA 17696 Insp GMP/IMP 17696/36548-0012[H] | COBRA BIOLOGICS LIMITED | KEELE ST5 5SP | 2020-12-16 | COMPLIANT |
| UK MIA(IMP) 17696 Insp GMP/IMP 17696/36548-0012[I] | COBRA BIOLOGICS LIMITED | KEELE ST5 5SP | 2020-12-16 | COMPLIANT |
| UK MIA(IMP) 17696 Insp IMP 17696/18644871-0001[I] | COBRA BIOLOGICS LIMITED | Newcastle ST5 5NT | 2019-01-29 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Oct 06, 2026
Financial Intelligence
"Planned Divestiture of CDMO and Cell Solutions Businesses
On February 25, 2026, Charles River Laboratories International, Inc."
"(the “Company”) announced that it has signed a definitive agreement to divest its contract development and manufacturing products and services (“CDMO”) and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments."
"The CDMO business provides services related to the production of advanced therapies for gene-modified cell therapies, as well as gene therapies including viral vectors and plasmid DNA; and the Cell Solutions business provides human-derived cellular materials used in the development and production of cell therapies."
"Our client base includes major global pharmaceutical companies, many biotechnology companies;
agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies
around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the nine months ended September 27, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the six months ended June 28, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the three months ended March 29, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our client base includes major global pharmaceutical companies, many biotechnology companies;
agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies
around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
(non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
(non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
Source: SEC EDGAR · Retrieved Oct 06, 2026
Frequently Asked Questions About ReciBioPharm
Does ReciBioPharm hold EMA or MHRA GMP certificates?
CDMO Signal tracks 3 MHRA GMP certificates for ReciBioPharm.
What is ReciBioPharm's CDMO Signal Score?
ReciBioPharm has a Signal Score of 88/100, based on quality, operations, financial stability, and capacity data.
Evaluating ReciBioPharm for a manufacturing program?
Use the free AI matchmaker to compare ReciBioPharm against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 81.0
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
Signal Score: 73.0
AAV, Lentiviral, Cell Therapy, mRNA, Monoclonal Antibody, Recombinant Protein
uBriGene Biosciences
Shanghai, CN · Boston, MA
Signal Score: 56.5
AAV, Lentiviral, Plasmid